Given the clear proliferative role of IL-36R agonists as determined by our in vitro findings, it is reasonable to conclude that IL-36Ra acts to reduce tumour burden by inhibition of IL-36-mediated proliferation of tumour cells. Here, IL1RL2 is linked to neoplasm.